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Abstract The polymorphism rs2569190 within the CD14
endotoxin (lipopolysaccharide, LPS) receptor gene is
associated with various disease conditions that are assumed
to rely on endotoxin sensitivity. In vitro experiments
suggest that the T allele sensitizes the host for exogenous
or endogenous LPS via an enhanced CD14 expression. To
prove the impact of this single nucleotide polymorphism in
its natural genomic context in vivo, two parameters of gene
transcription were analyzed in peripheral blood mononu-
clear cells (PBMC) from single healthy individuals: (a)
recruitment of RNA polymerase II by haplotype-specific
chromatin immunoprecipitation and (b) the relative amount
of transcripts by allele-specific transcript quantification
(ASTQ). RNA polymerase II was found to be twice as
much bound to the most prevalent haplotype, C-T-C-G, the
only one carrying a T at the position rs2569190 of interest.
ASTQ employing two independent read-out assays
revealed, however, similar transcript numbers originating
from C-T-C-G and non-C-T-C-G haplotypes. Total CD14
mRNA levels from freshly isolated PBMC, moreover, were
neither related to donors’ geno- nor haplogenotypes. Our
data argue for a functional impact of the rs2569190
polymorphism in terms of a stronger transcription initiation
on T allele gene variants even if preferential allele-specific
binding does not result in an increase in transcript numbers.
Endotoxin sensitivity associated with this genetic variation
appears not to rely solely on a cis-acting regulatory impact
of rs2569190 on CD14 gene transcription in PBMC.
Keywords SNP.LPS.Genepolymorphism.
Geneexpression.Innateimmunity
Introduction
A host might get into contact with bacterially derived
endotoxin (lipopolysaccharide, LPS) at the respiratory
endothelium via environmental exposure of LPS containing
dust, at the intestinal endothelium in the gut via the
commensal microflora, at liver sinusoids via the portal
vein, or in extravascular compartments when infection has
passed the microvascular endothelium. In mammals, endo-
toxin sensing is mediated by circulating LPS-binding
protein (LBP) which transfers LPS to a signaling receptor
complex composed of a glycosylphosphatidylinositol-
anchored membrane-associated form of CD14 (mCD14),
MD-2, and Toll-like receptor-4 (TLR4) on myeloid cells or
by LBP and a soluble form of CD14 (sCD14) which
transfers LPS to a MD-2/TLR4 receptor complex on
nonmyeloid cells. The soluble form of CD14 is either
shedded from cells bearing mCD14 or from direct
secretion. Since sCD14 is also able to compete with
mCD14 for LPS, a dual role for sCD14 has been proposed,
namely an inhibitory function on systemic responses by
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e-mail: smihm@med.uni-goettingen.depromoting LPS efflux from mCD14 and transferring it to
plasma lipoproteins and a stimulatory function on local
inflammation in tissues that may increase resistance to
bacteria [1]. Apart from that, LBP, CD14, and MD-2 have
been understood to function as upstream accessory mole-
cules that mediate physical ligand presentation, i.e., the
extraction of endotoxin monomers from the bacterial outer
membrane, and determine the amplitude of TLR4 activation
(reviewed in [2]).
Aside from genetic variations within the TLR4 gene
which have been shown to be associated with individual
endotoxin sensitivity [3, 4], many lines of evidence suggest
that also genetic variations within the CD14 gene do
determine the outcome of LPS exposure. For instance,
healthy individuals with the TT genotype at the variant
position rs2569190 have higher serum baseline levels of
sCD14 than those with the CC genotype [5], TT homozy-
gous children who were skin test positive to local
aeroallergens have significantly lower total IgE levels when
compared to C allele carriers [6], and in Finish children, a
gene–environment interaction between T allele carriers and
Helicobacter pylori antibodies on serum total IgE was
shown [7]. The same polymorphism has been shown to be
associated with alcoholic or cryptogenic chronic liver
disease progression [8–11]; it is supposed that the T allele
confers susceptibility to endogenous gut-derived LPS via
an enhanced expression of CD14 on liver cells thus
promoting progression of a chronic liver disease. By
applying electrophoretic mobility shift assays (EMSA), this
SNP has been found to lie within a GC box that contains a
binding site for Sp1, Sp2, and Sp3 transcription factors. A
DNA element containing the T allele was found to favor
transcription factor binding. Moreover, luciferase reporter
gene assays revealed the T allele DNA element to promote
gene transcription in monocytic cells via an enhanced
affinity to Sp1 and Sp2 [6, 12].
This study aimed at investigating of whether the variant
position rs2569190 confers allele-specific gene expression
also in a natural genomic context, i.e., whether it can be
regarded as a regulatory polymorphism. The majority of
SNPs which influence illness are assumed to be regulatory
(rSNP) meaning that they lie outside the amino acid coding
regions of genes and modify the expression level of
transcripts [13]. By taking further SNPs within the CD14
gene and nearby regions with relevant minor allele
frequencies (MAF; >0.1) into account, two parameters of
gene transcription were analyzed in freshly prepared human
peripheral blood mononuclear cells (PBMC). First,
haplotype-specific chromatin immunoprecipitation (Haplo-
ChIP) using antibodies directed against serine 5 phosphor-
ylated RNA polymerase II was applied to assess
transcription initiation [14, 15]. Second, allele-specific
transcript quantification (ASTQ) was applied to quantify
the relative numbers of transcripts that have been generated
from the two allelic gene variants. Both techniques
circumvent intrinsic errors in interindividual comparisons,
since comparison of alleles is made within rather than
between samples [16]. Nonetheless, total numbers of CD14
transcripts were also assessed with regard to the blood
donors’ geno- and haplogenotypes.
Materials and methods
Blood donors
Samples of 30 ml venous blood were taken from 42 healthy
Caucasian blood donors (20 female, 22 male; mean age
31.8 years, range 23–57) who gave a written informed
consent. The study was approved by the local ethical
committee and conformed to the ethical principles of the
2000 Declaration of Helsinki.
HaploChIP [17]
Chromatin immunoprecipitation was conducted using the
ChIP-IT Express kit (Active Motif, Rixensart, Belgium)
according to the supplier’s protocol. In brief, 1–10×10
6 cells
were cross-linked using 0.37% formaldehyde for 6 min at
room temperature. Fixation reactions were stopped by
adding glycine. Cells were washed once in ice-cold PBS,
resuspended in ice-cold lysis buffer, and subjected to dounce
homogenization to release the nuclei. Pelleted nuclei were
r e s u s p e n d e di nd i g e s t i o nb u f f e ra n di n c u b a t e di na n
enzymatic shearing cocktail for 10 min at 37°C. After
centrifugation, sheared chromatin was stored in aliquots
at −80°C until further use for immunoprecipitation or as
control “input” DNA.
Chromatin corresponding to 1×10
6 cells was incubated
with an antibody directed against serine 5 phosphorylated
RNA polymerase II or with a control mock (IgG) antibody,
and antibody-bound protein/DNA complexes were precip-
itated through use of magnetic protein G-coated beads. The
captured chromatin was then subjected to reverse cross-
linking and protease K digestion and taken up in a final
volume of 100 μl.
Input DNA (0.8 μl) and antibody captured DNA (8 μl)
were amplified by polymerase chain reaction (PCR) in
100 μl reactions using the primers rs2569190 for 5′-GAC
ACA GAA CCC TAG ATG CCC T-3′ and rs2569190 rev
5′-GTG AAC TCT TCG GCT GCC TC-3′. Cycling
conditions were a 2-min denaturation at 94°C, 28 cycles
of 30 s denaturation at 94°C, and 1 min annealing and
elongation at 60°C followed by a final elongation step for
7 min at 60°C. PCR products were subjected to restriction
fragment length polymorphism (RFLP) analysis. The
816 J Mol Med (2009) 87:815–824products (201 bp) were digested with HaeIII (Fermentas,
St. Leon-Rot, Germany) overnight. Samples were analyzed
in the Agilent 2100 bioanalyzer using the DNA 1000
LabChip kit (Agilent Technologies, Böblingen, Germany)
according to the supplier’s instructions.
Preparation of PBMC and isolation of total cellular RNA
PBMC from approximately 30 ml of heparinized peripheral
blood were prepared by Ficoll density centrifugation using
guanidinium isothiocyanate, and total cellular RNA was
isolated by CsCl density gradient ultracentrifugation essen-
tially as described [18].
ASTQ
Discrimination of transcripts using rs4914 as a marker SNP
was achieved by two different read-out assays. First,
discrimination and quantification of transcript variants were
achieved by real-time PCR using two differently fluores-
cence dye-labeled allele-specific minor groove binder
(MGB) probes for the SNP rs4914 (VIC 5′-CCT TGG
AGG AGC AC-3′, FAM 5′-CTT GGA GCA GCA CC-3′)
and gene-specific primers (rs4914 for 5′-CTG AAG CCA
AGG CAG TTT GAG T-3′, rs4914 rev 5′-TCC CAG CCT
GTG CAC GTT-3′). The assay was validated to be allele-
specific (absence of a signal from the second probe in
homozygote genomic DNA (gDNA) samples) and quanti-
tative as judged from reaction efficiencies and from
comparable signals in heterozygote gDNA samples (data
not shown).
Secondly, discrimination and quantification of transcript
variants was carried out by RFLP analyses: A product of
201 bp in size was generated by conventional PCR (CD14
exon2 for 5′-GCC CGA GGT GGATAA CCT G-3′, CD14
exon2 rev 5′-GTC CAT TCA TTA TTC TGT CTT GGA
TC-3′), purified and concentrated using the PrepEase gel
extraction kit (USB, Cleveland, OH, USA), and subjected
to digestion by SatI and Alw21I (Fermentas) for 2 h. SatI
cleaves C allele products into fragments of 55 and 146 bp
in size, whereas digestion by Alw21I leads to fragments of
106 and 95 bp in size for C allele products and to fragments
of 106, 50, and 40 bp in size for G allele amplicons,
respectively. Samples were separated and analyzed in the
Agilent 2100 bioanalyzer using the DNA 1000 LabChip kit
(Agilent Technologies). The relative amount of C and G
allele products and of hybrids was calculated.
Sequencing
Three overlapping regions of the CD14 gene and nearby
regions spanning 2,101 nucleotides (Fig. 1) were amplified
using gDNA as template, GoTaq Colorless Master Mix
(Promega GmbH, Mannheim, Germany), and 0.36 μMo f
primers each (for1 5′-GCC GAG ATC ATG GCA-3′, rev1
5′-ACC CTG ATC ACC TCC CCA C-3′; for2 5′-CCC
CTC CCT GAA ACATCC TT-3′, rev2 5′-GAG TGT GCT
TGG GCA ATG CT-3′; for3 5′-GGA CTT GCA CTT TCC
AGC TTG-3′, rev3 5′-GCA CAT AGC AGA CAT CCA
ATA AAG G-3′). Products were purified following the spin
protocol of the QIAquick PCR Purification Kit (Qiagen,
Hilden, Germany) and sequenced using an automated
sequencer (SeqLab, Göttingen, Germany). Alignments and
analyses were done using the Basic Local Alignment
Search Tool program of National Center for Biotechnology
Information (NCBI; National Institutes of Health, Bethesda,
MD, USA) and version 2.01 of the software Chromas LITE
(Technelysium Pty Ltd, Tewantin, QLD, Australia).
Genotyping
Genomic DNA was purified from whole blood samples
using the QIAamp DNA Blood Mini Kit following the
blood and body fluid spin protocol (Qiagen). Typically,
genotype determinations were performed by using 10 ng of
PBMC-derived gDNA.
Genotyping of the variant position of interest, rs2569190,
was carried out by allelic discrimination in 5′-nuclease real-
time PCR assays in the sequence detection system ABI prism
7000 (Applied Biosystems, Darmstadt, Germany) according
to the supplier’s instructions. In brief, gDNA was amplified
with 0.36 μM of primers each (forward 5′-CTA GAT GCC
CTG CAG AAT CCT T-3′,r e v e r s e5 ′-CCC TTC CTT TCC
TGG AAA TAT TGC A-3′) using the TaqMan Universal
Master Mix (Applied Biosystems). Allelic discrimination was
achieved by adding 0.2 μM differentially fluorescence dye-
labeled allele-specific MGB probes (rs2569190: VIC 5′-CCT
GTTACG GTC CCC CT-3′, FAM 5′-CTG TTA CGG CCC
CCC T-3′).
Genotyping of the variant position rs4914, the marker
SNP for ASTQ, was performed in the sequence detection
system ABI prism 7000 by using a commercially available
TaqMan genotyping assay (C_8724832_10) according to
the supplier’s instructions. Discrimination of genomic DNA
and transcript variants at SNP rs705 within the imprinted
gene small nuclear ribonucleoprotein polypeptide N
(SNRPN) was carried out using a commercially available
genotyping assay from ABI (C_2066555_10).
Genotyping of the SNPs rs5744455 and rs2563298 was
performed by tetra-primer amplification refractory mutation
system (ARMS) PCR as introduced by Ye et al. [19]. In
brief, gDNA was used as template in conventional
amplification reactions using 0.18 μM of each primer
(primer rs574 tetra T for 5′ AAG GAA GGG GGA ATT
TTT CTT TAG CCT 3′, primer rs574 tetra C rev 5′ GGT
AGA ATT AGG TTC AAG AAA AGG AAG GTG 3′,
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CTC TAT CTC A 3′, primer rs574 tetra rev 5′ CAT TTC
TTT GAC TTC TTC CTT GTC TTG G 3′ for rs5744455,
and primer rs2563 tetra G for 5′ CCC ACC TTT ATT AAA
ATC TTA AAG AAC AGG 3′, primer rs2563 tetra T rev
5′ TAA AGG TCT GTT AAA TGA ATG ACA CGA AA
3′, primer rs2563 tetra for 5′ TTT GCC TAA GAT CCA
AGA CAG AAT AAT G 3′, and primer rs2563 tetra rev 5′
TTT CTT AGG GAG TTA GGATGA AGA AAG C 3′ for
rs2563298). Amplicons were separated in 4% agarose gels.
Product patterns of 277/142, 277/142/192, and 277/192 bp
correspond to CC, CT, and TT genotypes of rs5744455 and
patterns of 247/143, 247/143/163, and 247/163 bp to GG,
GT, and TT rs2563298 genotypes, respectively.
Haplotyping
Haplotyping of the four respective SNPs was performed by
a combination of ARMS-PCR and genotyping assays.
Amplicons spanning the four SNPs of interest were
generated using rs5744455 and rs2569190 allele-specific
primers (rs574 tetra T for, rs574 tetra C for 5′-AAG GAA
GGG GGA ATT TTT CTT TAG CCC-3′, CD14 tetra3-rev
5′-TTT TCT TGA GGA GGA CAG ATA GGG TTT C-3′,
and rs2569190 C for 5′-CCT GCA GAA TCC TTC CTG
TTA CTG C-3′, rs2569190 T for 5′-CCC TGC AGA ATC
CTT CCT GTT ACT GT-3′, CD14 tetra3-rev, respectively)
in a conventional 25-μl PCR with an extended elongation
step (2.5 min 72°C) in a FlexCycler (Analytik Jena, Jena,
Germany). The amplicons were then subjected either to
5′-nuclease genotyping assays for rs2569190 or rs4914 (see
above) or to allele-specific amplification using tetra-primers
for rs2563298 (rs2563 tetra G for, rs2563 tetra T rev,
rs2563 tetra for, rs2563 tetra rev) in standard SYBR green
reactions.
Quantification of CD14 mRNA
Quantification of gene expression was performed by real-
time reverse transcriptase (RT)-PCR using the sequence
detection system ABI prism 7000 (Applied Biosystems) as
described [18]. Commercially available TaqMan gene
translated region untranslated region
CD14 [minus strand] gene
rs2569190
[C/T]
rs4914
[C/G]
rs5744455
[C/T]
139.993.637 139.991.451
rs2563298
[G/T]
human chrom 5
bases / contig position
SNP #
flanking sequencing primer
mRNA position with regard to
transcription start site
+1
mRNA position with regard to 
transcription start site
+1 +1362 +1484
transcript variant 2 (NM_001040021.1)
+95 +1455 +1606
transcript variant 1 (NM_000591.2)
a
b
exon / intron structure of variant 1
exon / intron structure of variant 2
Fig. 1 Schematic presentation of the structure of the CD14 gene and
of the two transcript variants. a In humans, the CD14 gene is located
on chromosome 5. The gene and the nearby 5′ and 3′ regions contain
four SNPs with MAFs >0.1 as indicated. Presence of these four SNPs
was confirmed by sequencing the indicated region. b Differential
splicing results in the existence of two transcript variants. Both of
them do contain rs4914, the marker SNP used for ASTQ. In transcript
variant 1, rs2569190 is located within the 5′UTR; because of its
intronic location in variant 2, rs2569190 is absent from transcript
variant 2
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(Hs00169122g1), CD11b (Hs00355885m1), and GAPDH
(Hs99999905m1) transcripts. To discriminate between
transcript variant 1 and 2, the TaqMan genotyping assays
for the SNPs rs2569190 and rs4914 were used in
parallel.
Results
Analysis of allele-specific transcriptional activity in situ
within a natural genomic context can be performed (a) on
the level of gDNA determining serine 5 phosphorylated
RNA polymerase II loading by HaploChIP technology as a
parameter of transcription initiation and (b) on the level of
mRNA determining the relative number of transcripts
originating from two gene copies by ASTQ. Both techni-
ques do not rely on the comparison of individuals but can
be carried out with material from single individuals who are
heterozygous at the position of interest. Whereas material
from individuals who are heterozygous at a respective
position is the only requirement for HaploChIP analyses,
ASTQ requires material from individuals who are addition-
ally heterozygous at a second SNP within the transcript (if
the SNP of interest is located, e.g., in a nontranscribed
regulatory region) and which must be used to discriminate
between transcripts derived from one or the other sister
chromosome. According to NCBI database, the CD14
transcript does contain a SNP suitable for ASTQ analysis,
rs4914, due to its location (Fig. 1) and due to a sufficiently
high MAF that should allow identification of double
heterozygous individuals. Accordingly, from a total of 42
healthy individuals who were genotyped at positions
rs2569190 and rs4914 (Table 1), 27 were found to be
heterozygous at rs2569190, and seven were found to be
heterozygous at both positions.
To cover all relevant SNPs within the CD14 gene and
the nearby 5′ and 3′ regions, e.g., with a MAF >0.1, which
might affect transcriptional activity, too, a panel of ten
samples was sequenced spanning a region of 2,101
nucleotides (see Fig. 1a). Alignment of the sequences
confirmed the four known SNPs rs5744455, rs2569190,
rs4914, and rs2563298 and the absence of any further with
relevant MAFs (data not shown). Genotyping of rs5744455
and rs2563298 (Table 1) and haplotyping of the four
respective loci was performed by a combination of ARMS-
PCR and 5′-nuclease genotyping and revealed a total of five
haplotypes (Table 2) resulting in a total of eleven haplo-
genotypes. C-T-C-G, the most frequent haplotype, was also
the only one carrying a T allele at the position of interest,
rs2569190.
HaploChIP analysis was performed on freshly prepared
PBMC from five healthy rs2569190 heterozygous blood
donors. Sheared chromatin from formalin-fixed cells served
as the “input” control. Input chromatin and chromatin that
was captured by an antibody directed against serine 5
phosphorylated RNA polymerase II, the “output” DNA,
were analyzed for the ratio of fragments carrying the C or
the T allele at position rs2569190 by RFLP analysis.
Whereas input chromatin was found to contain about the
same numbers of C and T variant fragments, the chromatin
of all volunteers that had been captured by anti-RNA
polymerase II antibodies was found to contain about twice
the numbers of T variant fragments (Fig. 2a) suggesting
that RNA polymerase II preferentially binds fragments
containing the rs2569190 T allele. As an additional control,
chromatin was also captured by a mock isotype (IgG)
antibody. The mock captured material was found to contain
nearly same amounts of C and T allele fragments (T/C
ratios of 1.18, 1.02, and 1.21) as with the input control (T/C
ratios 1.08, 1.10, and 1.11, respectively), while the output
material was found to contain more T allele fragments (T/C
ratios 1.90, 1.65, and 1.80, respectively; three independent
samples, data not shown). An analysis of HaploChIP data
with regard to haplogenotypes revealed the haplotype C-T-
C-G that one to be preferentially captured by anti-RNA
polymerase II antibodies, irrespectively of its genomic
counterpart (Fig. 2b). As an additional control for valida-
tion of HaploChIP results, input and output chromatins
were analyzed for the presence of two alleles of the SNP
rs705 located within the imprinted gene SNRPN. Whereas
input DNA contained similar amounts of each allele,
immunoprecipitated material captured by antibodies direct-
ed against serine 5 phosphorylated RNA polymerase II
contained only one allele as expected for the monoallelic
expression (see Fig. 3b, lower panel).
Genotype distribution
wt/wt wt/v v/v MAF P
b
rs5744455 [C/T]
a 22 (52.4%) 18 (42.9%) 2 (4.7%) 0.26 0.7
rs2569190 [C/T]
a 10 (23.8%) 27 (64.3%) 5 (11.9%) 0.44 0.07
rs4914 [C/G]
a 31 (73.8%) 9 (21.4%) 2 (4.8%) 0.15 0.23
rs2563298 [G/T]
a 22 (52.4%) 17 (40.5%) 3 (7.1%) 0.27 1
Table 1 Genotype distribution
among healthy blood donors
a[wild-type (wt), variant (v)]
bExact test for Hardy–Weinberg
equilibrium
J Mol Med (2009) 87:815–824 819To investigate whether a CD14 gene with a T allele at
position rs2569190 is more actively transcribed than the C
allele counterpart, ASTQ was performed on cDNA samples
from double heterozygous donors using rs4914 for dis-
crimination of transcripts. Discrimination of transcripts was
achieved by two independent read-out assays: by RFLP
analyses and by 5′-nuclease assays using differently labeled
allele-specific probes. The amounts of C and G allelic
transcript variants were not found to be different in all
samples studied as they were neither, expectedly, within
two samples from donors who are homozygous for the C
allele at rs2569190. These results were achieved irrespec-
tively of the technique applied (Fig. 3). Accordingly,
analysis of ASTQ data with regard to haplogenotypes
revealed that the number of transcripts originating from C-
T-C-G haplotypes does not exceed the number originating
from the other haplotypes (Fig. 3a). As a control for allelic
discrimination via RFLP analyses, cDNA samples from two
homozygotes were mixed at various ratios and analyses
yield expected results (Fig. 3a). As a control for allelic
discrimination via allele-specific probes, gDNA and cDNA
samples from individuals who were heterozygous at SNP
rs705 within the imprinted gene SNRPN were analyzed for
the ratio of the two alleles G and A. While in gDNA
samples both alleles were detectable at nearly same
amounts, corresponding cDNA samples contained either
one or the other (Fig. 3b, lower panel).
The existence of two different CD14 mRNA variants,
one of which carrying the SNP of interest within its 5′UTR
(variant 1) and the other not at all (variant 2; Fig. 1b), might
bias quantification of allelic transcript expression, e.g., by
different half life times. To determine the relative propor-
tion of transcript variants 1 and 2 within the cDNA
samples, cDNA samples were analyzed for the total amount
of CD14 transcripts on the one hand and for the amount of
transcript variant 1 by using an assay spanning rs2569190.
Whereas the number of transcripts containing rs4914 equals
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Fig. 2 Chromatin immunoprecipitation. a Formalin-fixed and enzy-
matically sheared chromatin from five healthy individuals heterozy-
gous at rs2569190 was immunoprecipitated with antibodies directed
against RNA polymerase II as described in the “Materials and
methods” section or was left untreated as an “input” control. Purified
input and output DNA samples were subjected to amplification
spanning rs2569190. Products of 201 bp in size were subjected to
restriction enzyme digestion with HaeIII. Restriction digest analysis
was carried out in a bioanalyzer yielding molar amounts of each
fragment as given. Undigested fragments represent DNA of the T
allele. Fragments of 49 and 152 bp in size represent DNA of the C
allele. Material from homozygous individuals (TT and CC) is shown
as a control for complete and specific enzymatic activity. b
Haplotypes (rs5744455–rs2569190–rs4914–rs2563298) of the five
donors are given
Haplotype
a Total number [n]
C-T-C-G 37
T-C-C-G 22
C-C-G-T 13
C-C-C-T 10
C-C-C-G 2
Table 2 Haplotype distribution
among the healthy individuals
under study
ars5744455–rs2569190–
rs4914–rs2563298
820 J Mol Med (2009) 87:815–824the number of total CD14 mRNA, the number of nucleic
acids containing rs2569190 was about 100-fold lower and
in the range of residual gDNA (Fig. 4). PBMC thus were
found to contain nearly exclusively transcript splice variant
2. Analysis of total CD14 mRNA from freshly isolated
PBMC failed to reveal a significant relationship with either
the four single SNPs and with haplogenotypes when blood
donors are divided into groups with none, one, or two C-T-
C-G haplotypes (Fig. 5).
Discussion
According to earlier knowledge, the SNP rs2569190 was
supposed to be located at position −159 within the promoter
of the CD14 gene. On the basis of association studies,
reporter gene assays, and EMSAs, this SNP was suggested
to affect transcriptional activity by a differential binding of
Sp1, Sp2, and Sp3 transcription factors [6, 8–10, 12].
Intriguingly, the impact of this SNP was shown to be
different in monocytes and hepatoma cells, most probably
due to a cell type specific different transcription factor
pattern [12]. According to more recent knowledge,
rs2569190 is located downstream of the transcription start
site, and two splice variants do exist (Fig. 1). Its relative
position within the (im-) mature transcripts depends on the
splice variant; while rs2569190 is located within the 5′
UTR of the transcript variant 1, this SNP is lacking in
transcript variant 2 due to its intronic position.
PBMC were found to contain variant 2 CD14 transcripts
(Fig. 4). Because of the absence of that SNP within the
transcript, an effect of rs2569190 on transcript stability in
PBMC can be ruled out. On the DNA level, the SNP might
affect transcription factor binding as it is located in a
transcription factor binding motif, a GC box, known to bind
transcription factors Sp1, Sp2, and Sp3. LeVan et al. have
shown both in EMSAs and in reporter gene assays that the
T allele confers higher transcriptional activity in a mono-
a
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Fig. 3 ASTQ analyses. The relative amount of mRNA species
carrying the C or the G allele at position rs4914 isolated from freshly
prepared human PBMC samples was analyzed by RFLP and by 5′-
nuclease assays using allele-specific probes. a RFLP data for all seven
double heterozygous individuals are given as the ratio of rs4914 C/G
alleles. Samples for two individuals homozygous at position
rs2569190 (#8 and #9) as well as corresponding gDNA samples
served as controls. cDNA samples that had been adjusted for the
amount of CD14 mRNA by quantitative gene expression assays were
mixed at various ratios yielding expected C/G ratios. Haplogenotypes
are indicated. b 5′-Nuclease assays were performed in triplicates. Data
from one representative determination are given for two representative
samples (#5 and #6; top), for two homozygous controls (#8 and #9;
middle), and for a control of the imprinted gene SNPRN for genomic
and cDNA and for HaploChIP material (bottom). ΔCT values for the
rs4914 C (blue) and G alleles (red) in cDNA samples were not
significantly different from the respective gDNA control
J Mol Med (2009) 87:815–824 821cytic cell line by preferential binding of the activating Sp1
and Sp2 transcription factors [12].
For the in vivo situation, i.e., in a natural genomic context,
we found a stronger recruitment of RNA polymerase II to T
allele variants. Transcription is known to follow a complex
phosphorylation/dephosphorylation cycle in which RNA
polymerase II is underlying a recycling process [15]. In brief,
after assembly onto promoter sequences with general
transcription factors (preinitiation), the RNA polymerase II
core enzyme is phosphorylated on serines at position 5 by
CDK7. Later on, after initiation of transcription, elongation
requires phosphorylation on serines at position 2 by CDK9, a
subunit of a transcription elongation factor. Polyadenylation
signals transcription to terminate, to relieve RNA polymerase
II off its template, and finally to be dephosphorylated.
HaploChIP analyses were performed using an antibody
directed against serine 5 phosphorylated RNA polymerase
II. Our data thus indicate that in the in vivo situation, the T
allele confers stronger transcription initiation than the wild-
type allele. Given that transcription factor binding might
CD14   total
CD14   rs4914
CD14   rs2569190
IRF-1   promoter
CT = 6.1
Number of cycles
F
l
o
u
r
e
s
c
e
n
c
e
 
i
n
t
e
n
s
i
t
y
threshold
CD14   total
CD14   rs4914
CD14   rs2569190
IRF-1   promoter
Δ
threshold
Fig. 4 Relative proportions of CD14 splice variants within PBMC
cDNA samples. cDNA samples from seven double heterozygous
individuals were analyzed for the amount of nucleic acids detected by
an assay specific for total CD14 mRNA, by an assay specific for a
region spanning rs4914, by an assay specific for a region spanning
rs2569190, and by an assay specific for gDNA (IRF-1 promoter). The
amount of products containing rs4914 equals the amount of total
CD14 mRNA, whereas the amount of products containing rs2569190
equals that of gDNA
Fig. 5 CD14 mRNA expression in healthy donors with regard to their
(haplo-)genotypes at four variant positions. Total CD14 mRNA was
quantified in PBMC samples from 42 healthy blood donors using a
commercially available gene expression assay by real time RT-PCR.
Data were analyzed with regard to genotypes at the four respective
positions and with regard to haplogenotypes as indicated. CD14
mRNA expression was not found to be different when donors with
different (haplo-)genotypes were compared to each other, irrespec-
tively of whether data were related to GAPDH as a reference transcript
as shown or whether they were related to CD11b as a reference.
Medians are given; for rs5744455 and rs4914, medians refer to wild-
type homozygotes and variant allele carriers, respectively
b
822 J Mol Med (2009) 87:815–824stabilize RNA polymerase II binding, our data are thus in
line with the findings by LeVan et al. [12].
By taking the number of transcripts as an end-point of
transcription and by using two independent techniques for
allelic discrimination, however, we found similar amounts of
allelic mRNAvariants.Thisfinding is inaccordancewith data
on total CD14 transcripts which do not differ in PBMC from
donors with different genotypes (Fig. 5). We thus suppose
that the T allele, or the C-T-C-G haplotype, might be
advantageous for transcription initiation but not necessarily
relevant for CD14 mRNA expression at least in PBMC.
While the rs2569190 T allele gene copy has been
demonstrated to be preferentially loaded by RNA polymerase
II in PBMC, endotoxin sensitivity appears not to be related to
allele-specific CD14 gene expression in PBMC. This finding
is in line with others showing different effects of regulatory
variants in different tissues (reviewed in [16]). As outlined in
the introduction, endotoxin sensing is not only mediated by
mCD14 expressing myeloid cells but also by sCD14 able to
transfer LPS to TLR4/MD2 expressing nonmyeloid cells
lacking mCD14. Moreover, circulating sCD14 is known to
inhibit systemic inflammatory responses to LPS via its
ability to remove LPS from mCD14 and to transfer it to
plasma lipoproteins which mediate clearance [1]. Thus, the
associations of rs2569190 TT genotype with higher sCD14
levels and with lower levels of IgE might reflect an effect of
that SNP independent on myeloid mCD14 but dependent on
nonmyeloid, e.g., hepatic, sCD14 expression or action.
As sCD14 is described to have stimulatory effects in
extravascular compartments, the association of rs2569190 T
allele and progression in alcoholic liver disease might be also
due to a better sensing of (endogenous) LPS from the gut via
sCD14-mediated transfer of LPS to nonmyeloid liver cells.
Based on the observation that hepatic stellate cells express
TLR4 and respond to its stimulation, it has been suggested
that TLR-mediated direct stellate cell activation is a major
pathway to induce liver fibrosis [20, 21].
Several lines of evidence indicate that hepatocytes are the
sourceofsCD14[22–24]. To address the impact of rs2569190
on hepatic transcriptional activity of the CD14 gene, ASTQ
analyses in liver tissue samples, e.g., from patients with a
diagnosis of absence of liver disease, are required.
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